Home/Tvardi Therapeutics/Michael J. Lewis, Ph.D.

MJ

Michael J. Lewis, Ph.D.

Co-Founder

Tvardi Therapeutics

Therapeutic Areas

Fibrosis Oncology Inflammatory Diseases

Tvardi Therapeutics Pipeline

Drug	Indication	Phase
TTI-101	Idiopathic Pulmonary Fibrosis (IPF)	Phase 2
TTI-102	Undisclosed Inflammatory/Fibrotic	Preclinical
Korsuva (difelikefalin)	Chronic Kidney Disease-Associated Pruritus (CKD-aP)	Marketed
Oral Korsuva	Notalgia Paresthetica & CKD-aP	Phase 2/3

Leadership Team at Tvardi Therapeutics

Imran Alibhai, Ph.D.

Chief Executive Officer

Ronald A. DePinho, M.D.

Co-Founder and Director

David J. Tweardy, M.D.

Co-Founder and Chief Scientific Officer

Keith T. Flaherty, M.D.

Scientific Advisory Board Member

View full Tvardi Therapeutics profile